Dr. Norman Wolmark

• 
  www.colorectalcancerupdate.com/nsabp_symposium/2006/1/p - [Cached Version]
  Published on: 1/1/2006    Last Visited: 2/9/2008  

  Norman Wolmark, MD Zip file
  ...
  Norman Wolmark, MD

• 
  www.breastcancerupdate.com/medonc/2008/5/wolmark.asp - [Cached Version]
  Published on: 1/1/2008    Last Visited: 2/7/2009  

  Norman Wolmark, MD Breast Cancer Update 5 | 2008
  
  BreastCancerUpdate.com
  ...
  You are here:Home: BCU 5 | 2008: Norman Wolmark, MD
  
  Norman Wolmark, MD
  ...
  DR WOLMARK: The BETH study opened recently (5.1).
  ...
  DR WOLMARK: Both agents are concerns. The NSABP and the CIRG are offering TCH as the template.
  ...
  DR WOLMARK: I have some deep-seated thoughts on this issue.
  ...
  DR WOLMARK: Sarah Cannon and US Oncology are evaluating six cycles of TAC versus six cycles of TC, but will that be a definitive trial?
  ...
  DR WOLMARK: This work by Soon has far-reaching ramifications that I believe challenge some of the concepts that many people thought were inviolate.
  ...
  DR WOLMARK: This trial will evaluate patients considered to be at high risk based on the observation that they did not achieve a pathologic complete response, either in the primary breast or in the axillary nodes, after preoperative therapy.
  ...
  Norman Wolmark, MD

• 
  www.cancerwatch.org/index.cfm?CFID=18256389&CFTOKEN=768 - [Cached Version]
  Last Visited: 10/1/2008  

  Norman Wolmark, at the American Society of Clinical Oncology annual meeting in Chicago.

• 
  www.cancerquilt.org/aboutus_content/aboutusMainContent. - [Cached Version]
  Published on: 2/22/2008    Last Visited: 2/22/2008  

  Norman Wolmark, MD Chair, National Surgical Adjuvant Breast and Bowel Project (NSABP)

• 
  www.wpahs.com/news/releases/index.cfm?mode=view&article - [Cached Version]
  Published on: 2/9/2007    Last Visited: 1/2/2008  

  Surgical Oncology - Mark Roh, M.D.,(Liver Cancer)(AGH) and Norman Wolmark, M.D. (Breast Cancer) (AGH)

• 
  www.colorectalcancerupdate.com/Patients2007/1/interview - [Cached Version]
  Published on: 1/1/2007    Last Visited: 2/9/2008  

  You are here: Home: CQAC 1 | 2007: Inteview with Norman Wolmark, MD
  
  Select Excerpts from the Interview with Dr Wolmark
  
  Track 7 (See Figure 1)
  ...
  DR WOLMARK: I believe it underscores a disconnect.
  ...
  DR WOLMARK: We may not have as much support in the number of patients treated.
  ...
  DR WOLMARK: I'm not sure we have to analyze what's going through their minds, but we do need to assure ourselves that they understand the information we're presenting.
  ...
  DR WOLMARK: Absolutely, and one has to respect that.
  ...
  DR WOLMARK: I was struck by that result, but I wasn't surprised by it.
  ...
  DR WOLMARK: I would have expected a difference, yet there was none.
  ...
  DR WOLMARK: I wasn't surprised, but a consistent trend is evident â€" that regardless of whether they are medical oncologists or clinical investigators, they underestimate the desire of their patients to proceed with chemotherapy.
  ...
  DR WOLMARK: I believe that's useful information that we can share with patients for whom we're contemplating chemotherapy, as a tool to put these percentages into proportion and tell them, "This is what other patients who have received chemotherapy thought of the toxicity."
  ...
  DR WOLMARK: Our trial data can talk about "an eight percent incidence of Grade III neurotoxicity," but what does that actually mean?
  ...
  DR WOLMARK: The fact that patients were happy and awarded high marks to the medical oncologists is gratifying.
  ...
  DR WOLMARK: Perhaps it's a matter of wanting information specifically tailored to their personal situations, because the survey indicates that patients respect their physicians as capable individuals.
  ...
  DR WOLMARK: Precisely.
  
  Track 12 (See Figure 11)
  ...
  DR WOLMARK: That underscores the fact that the vast majority of patients are not apprised of clinical trials as an option.
  ...
  Norman Wolmark, MDSelect publications

• 
  www.colorectalcancerupdate.com/nsabp_symposium/2006/1/o - [Cached Version]
  Published on: 2/12/2009    Last Visited: 2/12/2009  

  Norman Wolmark, MD

• 
  www.coloncancertoday.com/ms/news/627595/main.html - [Cached Version]
  Published on: 7/14/2009    Last Visited: 7/14/2009  

  We failed to provide patients with a novel intervention which would increase the cure rate," said that author, Dr. Norman Wolmark, chairman of the department of human oncology at Allegheny General Hospital in Pittsburgh and chairman of the National Surgical Adjuvant Breast and Bowel Project (NSABP), which conducted the study.
  ...
  But at a news conference, held Saturday at the annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Fla., Wolmark pressed the point that Avastin (bevacizumab) did bring an improvement while it was given to patients. However, this benefit vanished once patients stopped taking the drug.
  
  "The hoped-for endpoints of the trial -- to increase the cure rate of early stage colon cancer -- were simply not met," he said. "Having said that, it is clear that there was a statistically significant transient benefit in disease-free survival during the time that [Avastin] was given, so it was effective. But, that efficacy disappeared after the year that it was given."
  
  At one year, there was an absolute difference in disease-free survival of only 3.6 percent in favor of Avastin. And the jury may still be out on whether or not Avastin's benefits might last if patients receive it for a longer period of time. "Clearly, strong consideration should be given to clinical trials that use [Avastin] for periods of time beyond the one year that was used in this protocol," Wolmark said.
  
  The trial, a large one involving 2,710 patients from 245 institutions, was funded by the U.S. National Cancer Institute. Drug makers Genentech and Sanofi-Aventis provided the treatment drug; Wolmark has consulted for Genentech.
  ...
  Wolmark said his group hoped to start a trial soon looking at Avastin in the same population over two years.
  ...
  SOURCES: May 30, 2009, American Society of Clinical Oncology news conference with Norman Wolmark, M.D., chairman, department of human oncology, Allegheny General Hospital, Pittsburgh; Philip B. Paty, M.D., attending surgeon and vice chairman of clinical research, Memorial Sloan-Kettering Cancer Center, New York City; John Neoptolemos, M.D., head, division of surgery and oncology, University of Liverpool, Liverpool, U.K.; study abstracts

• 
  www.colorectalcancerupdate.com/GI_2007/download-audio/ - [Cached Version]
  Published on: 8/1/2008    Last Visited: 8/1/2008  

  Go to interview with Alan P Venook, MD | Go to interview with Axel Grothey, MD | Go to interview with Norman Wolmark, MD | Go to interview with Richard M Goldberg, MD | Go to interview with Neal J Meropol, MD | Go to interview with Howard S Hochster, MD
  ...
  Go to interview with Norman Wolmark, MD
  ...
  Norman Wolmark, MD Professor and ChairmanDepartment of Human OncologyAllegheny General Hospital

• 
  www.colorectalcancerupdate.com/GI_2007/ - [Cached Version]
  Published on: 8/1/2008    Last Visited: 8/1/2008  

  Norman Wolmark, MD
  ...
  Discussant: Norman Wolmark , MD

Page:  1 2 3 4 5